news
FDA biologics center tries to calm waters after leadership turmoil
Karim Mikhail took over as acting director of the FDA's Center for Biologics Evaluation and Research (CBER), which regulates everything from vaccines to gene therapies. He's got his work cut out for him, aiming to boost staff morale and revisit some of his predecessor's controversial decisions. This could impact timelines for new biological products hitting the market.
Karim Mikhail took over as acting director of the FDA's Center for Biologics Evaluation and Research (CBER), which regulates everything from vaccines to gene therapies. He's got his work cut out for him, aiming to boost staff morale and revisit some of his predecessor's controversial decisions. This could impact timelines for new biological products hitting the market.
The architecture take
The FDA's CBER, which oversees a ton of cutting-edge health tech—you know, the stuff that either extends your life or just tries to make it less miserable—just got a new boss. After a seriously bumpy ride with the last guy, Mr. Mikhail is basically trying to hit the reset button. What does this mean for your body? It affects how quickly new peptides, gene therapies, and even some fancy new probiotics get through the regulatory gauntlet. A smoother CBER means faster access to things that could actually move the needle on longevity and chronic conditions. But it also means regulators need to be sharp, not just fast. Keep an eye on what products clear their reviews next, because that's the real signal.